X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CIPLA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CIPLA SUN PHARMA/
CIPLA
 
P/E (TTM) x 23.6 44.7 52.8% View Chart
P/BV x 3.4 3.8 89.9% View Chart
Dividend Yield % 0.7 0.3 199.0%  

Financials

 SUN PHARMA   CIPLA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
CIPLA
Mar-17
SUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs842622 135.4%   
Low Rs572458 124.9%   
Sales per share (Unadj.) Rs131.6181.9 72.4%  
Earnings per share (Unadj.) Rs32.712.9 254.1%  
Cash flow per share (Unadj.) Rs38.029.3 129.5%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.50.4 133.6%  
Book value per share (Unadj.) Rs152.7155.7 98.1%  
Shares outstanding (eoy) m2,399.26804.51 298.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.43.0 180.9%   
Avg P/E ratio x21.642.0 51.5%  
P/CF ratio (eoy) x18.618.4 101.1%  
Price / Book Value ratio x4.63.5 133.5%  
Dividend payout %10.715.5 68.9%   
Avg Mkt Cap Rs m1,696,877434,516 390.5%   
No. of employees `00017.523.0 76.0%   
Total wages/salary Rs m49,02326,338 186.1%   
Avg. sales/employee Rs Th18,028.36,349.1 284.0%   
Avg. wages/employee Rs Th2,798.81,143.0 244.9%   
Avg. net profit/employee Rs Th4,479.5449.3 996.9%   
INCOME DATA
Net Sales Rs m315,784146,302 215.8%  
Other income Rs m6,2322,287 272.5%   
Total revenues Rs m322,016148,589 216.7%   
Gross profit Rs m100,89324,758 407.5%  
Depreciation Rs m12,64813,229 95.6%   
Interest Rs m3,9981,594 250.8%   
Profit before tax Rs m90,47912,222 740.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m99-70 -142.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1161,798 674.0%   
Profit after tax Rs m78,46210,354 757.8%  
Gross profit margin %31.916.9 188.8%  
Effective tax rate %13.414.7 91.0%   
Net profit margin %24.87.1 351.1%  
BALANCE SHEET DATA
Current assets Rs m329,53787,370 377.2%   
Current liabilities Rs m178,87033,081 540.7%   
Net working cap to sales %47.737.1 128.6%  
Current ratio x1.82.6 69.8%  
Inventory Days Days7987 90.8%  
Debtors Days Days8362 133.6%  
Net fixed assets Rs m204,766111,567 183.5%   
Share capital Rs m2,3991,609 149.1%   
"Free" reserves Rs m363,997123,645 294.4%   
Net worth Rs m366,397125,254 292.5%   
Long term debt Rs m14,36136,454 39.4%   
Total assets Rs m614,102209,532 293.1%  
Interest coverage x23.68.7 272.6%   
Debt to equity ratio x00.3 13.5%  
Sales to assets ratio x0.50.7 73.6%   
Return on assets %13.45.7 235.5%  
Return on equity %21.48.3 259.1%  
Return on capital %24.88.5 292.2%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m44,11851,066 86.4%   
Fx outflow Rs m24,48417,678 138.5%   
Net fx Rs m19,63433,388 58.8%   
CASH FLOW
From Operations Rs m70,82223,824 297.3%  
From Investments Rs m-42,216-13,127 321.6%  
From Financial Activity Rs m-22,854-13,239 172.6%  
Net Cashflow Rs m6,107-2,478 -246.4%  

Share Holding

Indian Promoters % 63.7 16.0 398.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.1 12.2 42.0%  
FIIs % 23.0 23.7 97.0%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.3 26.2 31.7%  
Shareholders   133,026 161,166 82.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - SANOFI INDIA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS